Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Strata Critical Medical, Inc.SRTA · Entity 5512 | Director | July 30, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Strata Critical Medical, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 97,671 |
Reported balance
After 2026-07-30 transaction · row 1
1 source rowRow 1 · 2026-07-30 · Grant · Acquired 44,438 · Balance 97,671 F1: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting of Stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 30, 2026 Filed Aug 3, 2026 20:07 UTC | Strata Critical Medical, Inc. SRTA · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 44,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-051826 · wk-form4_1785787640.xml · nonDerivative · entry 1 Cook William L. III · CIK 0002096995 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,671 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting of Stockholders. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:21 UTC | Strata Critical Medical, Inc. SRTA · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 33,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-055370 · wk-form4_1764883275.xml · nonDerivative · entry 2 Cook William L. III · CIK 0002096995 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,233 F2 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2027 Annual Meeting of Stockholders. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:21 UTC | Strata Critical Medical, Inc. SRTA · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 20,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-055370 · wk-form4_1764883275.xml · nonDerivative · entry 1 Cook William L. III · CIK 0002096995 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,076 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting. 100% of the RSUs will become vested on the date of the Issuer's 2026 Annual Meeting of Stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.